Please see below. 

Thanks, 
Drew

Drew Grill | Program Coordinator II  
DHARS Administative Director
Department of Physical Therapy
UAB | The University of Alabama at Birmingham
SHPB 381 | 1720 2nd Ave So | Birmingham, AL 35294-1212
P: 205.934.4644 | [log in to unmask] email address is being protected from spambots. You need JavaScript enabled to view it. 


-----Original Message-----
From: NIH Rehabilitation Research <[log in to unmask]> On Behalf Of Alison Cernich
Sent: Friday, November 30, 2018 1:32 PM
To: [log in to unmask]
Subject: HEAL Comparative Effectiveness Research

The NIH, as part of the Helping to End Addiction Long-Term (HEAL) initiative is planning to release a Funding Opportunity Announcement for clinical trials on comparative effectiveness research.   A Notice providing more information on the planned FOA was released and is available on the NIH Guide:   https://grants.nih.gov/grants/guide/notice-files/NOT-NS-19-022.html

The planned request for applications (RFA) will support effectiveness clinical trials that propose clinical trials to test the comparative effectiveness of existing therapies or effectiveness of existing or novel approaches for prevention and management of pain while reducing risk of addiction. The overall goal is to inform clinicians about the effectiveness of interventions or management strategies that reduce opioid use that will improve functional outcomes and reduce pain across the continuum of acute to chronic pain associated with many types of diseases or conditions, or pain presenting as a disease itself. 

This Notice encourages investigators with expertise in this area of clinical research to consider applying to this planned FOA. Collaborative teams combining expertise in pain management and large clinical trials will be crucial to the success of the studies.  The planned initiative will encourage UG3/UH3 phased cooperative research applications to conduct efficient, large-scale effectiveness trials to evaluate non-addictive therapies for pain that would reduce use of opioids. Awards will support a one-year milestone-driven planning phase (UG3), with transition to an implementation phase (UH3) of up to four years, contingent on meeting milestone and feasibility requirements of the planning phase. The UG3/UH3 application must be submitted as a single application.

Please refer to the contact list in the notice for inquiries

########################################################################

To unsubscribe from the REHAB-NIH list, click the following link:
http://list.nih.gov/cgi-bin/wa.exe?SUBED1=REHAB-NIH&A=1